Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. (TVTX) director Gary A. Lyons reported a proposed sale of 5,000 common shares, with an approximate sale date of August 17, 2026 and an aggregate market value of $310,700. The shares are listed as acquired from the issuer on August 17, 2026 through exercise of stock options, with cash as the payment method. The notice lists May 18, 2026 as the date of Rule 10b5-1 plan adoption or instruction.
Travere Therapeutics, Inc. is the subject of an amended Schedule 13G filing by Armistice Capital, LLC and Steven Boyd. The reporting persons disclose beneficial ownership of 1,572,539 shares of Travere common stock, representing 1.67% of the class, with shared voting and dispositive power over all reported shares and no sole voting or dispositive power.
Bank of America Corporation, through certain wholly owned subsidiaries, reported beneficial ownership of 5,439,155 shares of Travere Therapeutics, Inc. common stock on a Schedule 13G. This represented 5.8% of the class, based on 94,174,767 shares outstanding as of June 30, 2026, as reported by Travere in a Form 10-Q filed August 4, 2026.
Bank of America reported no sole voting or dispositive power over Travere shares. It reported shared voting power over 5,103,492 shares and shared dispositive power over 5,325,237 shares, reflecting positions held across subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware.
State Street Corporation reported its beneficial ownership of Travere Therapeutics, Inc. common stock. State Street, through its investment management subsidiaries, reported beneficially owning 4,256,224 shares of common stock, representing 4.6% of the class as of June 30, 2026.
The shares are held with no sole voting or dispositive power; State Street reported shared voting power over 4,010,969 shares and shared dispositive power over 4,256,224 shares. The filing indicates ownership of 5 percent or less of the class and identifies several State Street Global Advisors entities as the investment adviser subsidiaries through which the holdings are maintained.
FMR LLC and Abigail P. Johnson report beneficial ownership of TRAVERE THERAPEUTICS INC common stock on an amended Schedule 13G.
FMR LLC reports beneficial ownership of 7,142,482.22 shares of common stock, representing 7.7% of the class, with 6,173,667.45 shares having sole voting power and all 7,142,482.22 shares subject to sole dispositive power. Abigail P. Johnson reports sole dispositive power over the same 7,142,482.22 shares, with no voting power. The filing states that one or more other persons have rights to dividends or sale proceeds in these shares, but no such person has an interest exceeding five percent of the outstanding common stock.
Travere Therapeutics reported total revenue of $169.584 million for the quarter ended June 30, 2026, up from $114.449 million a year earlier. Net product sales were $161.352 million, led by FILSPARI at $141.078 million versus $71.887 million in 2025, while tiopronin products declined modestly. License and collaboration revenue fell to $8.232 million from $19.607 million. Operating income was $3.954 million, but a $40.008 million inducement expense on repurchasing 2029 convertible notes drove a net loss of $34.797 million, or $0.37 per share.
For the first six months of 2026, revenue was $296.782 million and net loss was $71.899 million. Net cash provided by operating activities improved to $17.705 million from an outflow of $37.211 million in 2025. At June 30, 2026, cash and cash equivalents were $117.735 million and available-for-sale marketable debt securities were $371.442 million. Convertible senior notes totaled $602.781 million (net), including $525.0 million of new 0.50% notes due 2032 and $94.875 million of 2.25% notes due 2029, while stockholders’ equity was $24.522 million.
Business updates include full FDA approval on April 13, 2026 of FILSPARI to reduce proteinuria in adults and pediatric patients with FSGS, where FILSPARI is the first and only FDA‑approved medicine. The pegtibatinase Phase 3 HARMONY Study resumed enrollment in early 2026 with the first new patient dosed in April. Key risks highlighted include heavy dependence on FILSPARI commercialization, clinical and regulatory uncertainty for pipeline programs, reimbursement and pricing pressures, manufacturing reliance on third parties, substantial funding needs, and ongoing regulatory and litigation exposure.
Travere Therapeutics reported second quarter 2026 results driven by FILSPARI demand in IgA nephropathy and FSGS. U.S. net product sales rose to $161.4 million from $94.8 million, including FILSPARI sales of $141.1 million, and 2,012 new patient start forms. A recognized inducement expense of $40.0 million related to 2029 convertible note repurchases contributed to a GAAP net loss of $34.8 million or $0.37 per share; non-GAAP net loss was $9.0 million or $0.10 per share. Cash, cash equivalents, and marketable securities totaled $489.2 million as of June 30, 2026, after issuing $525 million of 0.5% convertible notes due 2032 and repurchasing approximately $221 million of 2.25% notes due 2029.
Travere advanced its rare kidney disease portfolio. FILSPARI received U.S. approval in April 2026 to reduce proteinuria in FSGS patients without nephrotic syndrome, with a U.S. addressable population above 30,000 and a U.S. patent allowance expected to extend IgA nephropathy method-of-use coverage into October 2037. The pivotal Phase 3 HARMONY Study of pegtibatinase in classical homocystinuria continues enrolling, with topline data expected in 2H 2027. The company also closed an exclusive licensing and collaboration agreement for civorebrutinib, paying $112.5 million upfront for rights outside Greater China and certain Asian countries, and plans to study it across multiple immune-mediated kidney diseases.
Travere Therapeutics, Inc. reported that its chief accounting officer and principal accounting officer, Sandra Calvin, plans to retire after the filing of the company’s Annual Report on Form 10-K expected in February 2027. The company expects Vice President, Controller John Torell, a CFA and CPA, to assume the CAO and PAO roles, with the board planning to appoint him before her retirement to allow for an orderly transition of responsibilities.
Travere Therapeutics, Inc. chief medical officer Jula Inrig reported a bona fide gift of 468 shares of common stock to a donor-advised fund. The gift was authorized on June 16, 2026, and transferred on June 22, 2026, at a reported price of $0.00 per share. Following this charitable transfer, Inrig directly holds 112,770 shares of Travere Therapeutics common stock, indicating this was a relatively small, non-market transaction within her overall position.
Travere Therapeutics director Timothy Coughlin reported an option exercise combined with a share sale. He exercised stock options for 10,000 shares of common stock at an exercise price of $26.52 per share and sold 10,000 shares in an open-market transaction at a weighted average price of $50.0747 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025, indicating it was scheduled in advance. Following these transactions, Coughlin directly holds 56,250 shares of Travere Therapeutics common stock.